Drugs / IL-12
IL-12
English name Interleukin-12
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02483312 | Sep 2015 → Aug 2026 overdue | acute myeloid leukemia | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01266616 | Mar 2011 → Oct 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00991354 | Nov 2009 → Feb 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00455221 | Feb 2008 → Dec 2010 | chronic myeloid leukemia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00528489 | Oct 2007 → Jan 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00004070 | Jul 1999 → Nov 2000 | head and neck cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00057486 | Sep 1997 → Jun 2005 | HIV infectious disease, cryptosporidiosis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04357821 Background | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
Press releases naming this drug 16 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 | “IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12)” NCT04357821 ↗ |
| Known as | interleukin-12 | “interleukin-12 (IL-12) and is delivered by electroporation combined with intramuscular injection (IM-EP)” PMID 26761518 ↗ Feb 20161“Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients” NCT00057486 ↗ |
| Known as | rhIL-12 | “A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic...” NCT00057486 ↗ |
| Action | Activate | “IL-12 stimulates interferon gamma” NCT00057486 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-12 (rhIL-12)” NCT00057486 ↗ |
| Route | Subcutaneous | “The plasmids will be administered subcutaneously near the vaccination site 24 hours before vaccination” NCT00455221 ↗ |